Bristol Myers Squibb Reports Q3 2026 Results & Raises Full-Year Revenue Outlook

Bristol Myers Squibb Reports Q3 2026 Results and Increases Full-Year Revenue Guidance

Key Financial Highlights

• Total Revenues: Reached $13.07 billion, an increase of 7% year-over-year (both reported and excluding foreign exchange impact) compared to $12.22 billion in Q3 2025.
  • U.S. Revenue: $9.1 billion, up 9% YoY.
  • International Revenue: $4.0 billion, up 3% YoY (4% Ex-FX).
• Growth Portfolio: Generated $7.7 billion, increasing 12% year-over-year, led by strong momentum from Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos, and Opdualag.
• Legacy Portfolio: Totaled $5.4 billion, up 1% YoY, supported by Eliquis and offset by generic erosion across legacy assets.
• Diluted EPS:
  • GAAP EPS: $1.05, down 3% from $1.08 in Q3 2025.
  • Non-GAAP EPS: $1.35, compared to $1.63 in the prior-year period.
  • Both GAAP and non-GAAP EPS include a $(0.58) per share net impact from Acquired In-Process R&D (IPRD) charges and licensing income (compared to $(0.20) in Q3 2025).

Selected Product Revenue Highlights (Q3 2026)

• Opdivo (WW): $2,374 million (-6% YoY)
• Opdivo Qvantig (WW): $334 million (>200% YoY)
• Orencia (WW): $983 million (+2% YoY)
• Yervoy (WW): $793 million (+7% YoY)
• Reblozyl (WW): $750 million (+22% YoY)
• Breyanzi (WW): $526 million (+46% YoY)
• Opdualag (WW): $367 million (+23% YoY)

Updated Full-Year 2026 Guidance

• Total Revenues: Raised to a range of $49.75 billion to $50.25 billion.
• Non-GAAP Diluted EPS: Updated to $6.35 to $6.55, which includes an estimated $(0.60) per share net impact from Acquired IPRD charges and licensing income.